Current Concepts in Breast Cancer Genomics: An Evidence Based Review by the CGC Breast Cancer Working Group
Affiliations
- PMID: 32087595
- DOI: 10.1016/j.cancergen.2020.02.002
Abstract
Background: Genomic abnormalities in breast cancer have been described according to diverse conceptual frameworks, including histologic subtypes, clinical molecular subtypes, intrinsic DNA, RNA, and epigenetic profiles, and activated molecular pathways.
Methods: The Cancer Genomics Consortium (CGC) Breast Cancer Workgroup performed an evidence based literature review to summarize current knowledge of clinically significant genomic alterations in breast cancer using CGC levels of evidence. Targetable or disease-defining alterations were prioritized.
Results: We summarized genomic alterations in breast cancer within a framework of existing clinical tools for diagnosis, risk stratification, and therapeutic management. Using CGC levels of evidence, we catalog copy number profiles, gene expression profiles, and mutations in clinically significant genes. We also describe emerging molecular markers such as methylation profiling and immunotherapy biomarkers.
Conclusion: A summary of currently available information on breast cancer genomics will enhance precision medicine by serving as an interpretive resource for clinical laboratory geneticists, providing a foundation for future practice guidelines, and identifying knowledge gaps to address in future research.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
- Assessing Copy Number Aberrations and Copy Neutral Loss of Heterozygosity Across the Genome as Best Practice: An Evidence Based Review of Clinical Utility From the Cancer Genomics Consortium (CGC) Working Group for Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative and Myeloproliferative NeoplasmsR Kanagal-Shamanna et al. Cancer Genet 228-229, 197-217. PMID 30377088. - ReviewMultiple studies have demonstrated the utility of chromosomal microarray (CMA) testing to identify clinically significant copy number alterations (CNAs) and copy-neutral …
- Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic ImplicationsDH Hovelson et al. Eur Urol 74 (6), 741-753. PMID 30033047.Our results support the feasibility of clinically relevant integrative bladder cancer profiling and challenge the intrinsic nature of expression subtypes in histologicall …
- Technical Laboratory Standards for Interpretation and Reporting of Acquired Copy-Number Abnormalities and Copy-Neutral Loss of Heterozygosity in Neoplastic Disorders: A Joint Consensus Recommendation From the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)FM Mikhail et al. Genet Med 21 (9), 1903-1916. PMID 31138931.The detection of acquired copy-number abnormalities (CNAs) and copy-neutral loss of heterozygosity (CN-LOH) in neoplastic disorders by chromosomal microarray analysis (CM …
- A Decision Support Framework for Genomically Informed Investigational Cancer TherapyF Meric-Bernstam et al. J Natl Cancer Inst 107 (7). PMID 25863335. - ReviewRapidly improving understanding of molecular oncology, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an o …
- Assessing Copy Number Abnormalities and Copy-Neutral Loss-Of-Heterozygosity Across the Genome as Best Practice in Diagnostic Evaluation of Acute Myeloid Leukemia: An Evidence-Based Review From the Cancer Genomics Consortium (CGC) Myeloid Neoplasms Working GroupX Xu et al. Cancer Genet 228-229, 218-235. PMID 30344013. - ReviewStructural genomic abnormalities, including balanced chromosomal rearrangements, copy number gains and losses and copy-neutral loss-of-heterozygosity (CN-LOH) represent a …
.png)
No hay comentarios:
Publicar un comentario